Highlights from EBMT 2016: Immunotherapy
Summary of CLL trials presented at ASH 2016
New subtypes of acute lymphoblastic leukemia (ALL) – potential treatment identification by genomics
Remission maintenance with histamine dihydrochloride (HDC)/IL-2 therapy in AML
Precision medicine for MDS, what drugs for which patients?